Search Results

AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), announced today a strategic partnership with RoosterBio Inc., a leading supplier of human mesenchymal stem/stromal cells (hMSCs), highly engineered media, and bioprocess development services.

RoosterBio’s MSC-derived exosome bioprocess technology platform enables accelerated development of ShiftBio’s lead therapeutic candidate via a scalable cGMP manufacturing process in bioreactors, downstream purification, and analytical characterization.

RoosterBio Inc. announces a clinical supply and manufacturing collaboration agreement with pioneering gene circuit company Senti Biosciences, Inc. (Senti) to accelerate the clinical translation of Senti’s gene-modified cell therapies for ovarian cancer and other solid tumor indications. The collaboration will leverage RoosterBio’s human mesenchymal stem/stromal cell (hMSC) bioprocess systems, rapid product and process development platform, and

The start of 2020 has also brought the need for some companies in the pharma industry to acquire the next size up in building space as they expand their employee headcount.

Global GMP Cell Therapy Consumables Market is valued at US$ 17.98 Mn in 2023, and it is expected to reach US$ 139.19 Mn by 2031, with a CAGR of 29.3% during the forecast period of 2024-2031.